Cohance Lifesciences to invest $10 million to expand cGMP bioconjugation capabilities at U.S based subsidiary

12 Aug 2025 Evaluate

Cohance Lifesciences (with its subsidiaries, hereafter referred to as ‘Cohance’) is all set to make strategic investment of $10 million to expand cGMP bioconjugation capabilities at its U.S based subsidiary, NJ Bio. Aligned with the company’s long-term strategy, this investment advances Cohance’s global expansion in niche technology-led modalities, enhancing its ability to support innovators from early development through late-phase clinical supply. 

The build-out of a state-of-the-art, cGMP compliant bioconjugation suite at NJ Bio’s Princeton, New Jersey facility significantly strengthens the company’s capabilities to deliver fully integrated Antibody-Drug-Conjugate (ADC) solutions - from early phase payload-linker synthesis through to complete ADC manufacturing for clinical supply.

NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline. The engagement spans early-phase payload-linker development already underway and will advance to cGMP bioconjugation upon commissioning of the new suite. This collaboration underscores the customer’s confidence in NJ Bio’s ability to deliver complex chemistry solutions and end-to-end ADC manufacturing support for Phase 1 and Phase 2 clinical studies.

The new suite, designed to handle high-potent drug substances, will have the flexibility to manufacture up to 2 kg of ADCs, sufficient for clinical requirements once the program transitions to cGMP production in the expanded facility. The facility is expected to be operational by the end of Q4FY26, with related bioconjugation work commencing thereafter.

Cohance Lifesciences (Formerly, Suven Pharmaceuticals) is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialization. 


Cohance Lifesciences Share Price

542.20 -6.90 (-1.26%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×